A treatment combining two antibodies (casirivimab and imdevimab) is recommended for two specific groups of patients with COVID-19 by a WHO Guideline Development Group (GDG) panel of international experts and patients in The BMJ today. The first are patients with…
Read More
Study shows new obesity treatment semaglutide causes similar weight loss across different age groups
The STEP trials published over the past year have established the efficacy and safety of semaglutide in treating patients with obesity. A new study analysing the effects of this treatment in different age groups presented at this year’s European Congress…
Read More